Equities
Health CarePharmaceuticals & Biotechnology
  • Price (JPY)8,085.00
  • Today's Change-8.00 / -0.10%
  • Shares traded2.42m
  • 1 Year change+41.54%
  • Beta1.1249
Data delayed at least 20 minutes, as of Nov 29 2021 06:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The Company is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The Company mainly provides its products and services in Japan, Europe and North America markets.

  • Revenue in JPY (TTM)293.81bn
  • Net income in JPY115.61bn
  • Incorporated1919
  • Employees5.49k
  • Location
    Shionogi & Co Ltd3-1-8, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
  • Phone+81 662022161
  • Fax+81 662299596
  • Websitehttps://www.shionogi.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Recordati Industria Chimica e Farma SpA193.85bn48.40bn1.47tn4.36k30.367.8024.147.581.801.807.237.020.52661.665.30346,455.3013.1514.6316.4518.4172.7670.5124.9723.231.1719.840.424659.51-2.236.70-3.7512.3033.3411.84
Shanghai Fosun Pharmaceutical (Group)624.90bn84.18bn2.20tn32.26k28.553.48--3.521.851.8513.7315.190.41273.356.231,092,830.006.005.599.828.4550.9557.4114.5414.970.8761--0.336330.186.0219.1710.278.2929.146.09
Otsuka Holdings Co Ltd1.46tn147.02bn2.28tn33.15k15.181.129.751.56269.28269.282,697.973,658.270.54212.684.1244,139,960.005.604.566.795.5767.8966.9810.338.801.83--0.098148.151.90-0.063816.507.765.320.00
Shionogi & Co Ltd293.81bn115.61bn2.52tn5.49k21.292.7719.248.58380.09380.09967.232,922.630.30111.433.7153,565,720.0011.8614.0413.0615.8180.7281.1839.3833.506.03--0.008225.39-10.86-0.8396-8.4610.9016.8911.74
Astellas Pharma Inc1.29tn119.36bn3.52tn15.46k29.432.4718.242.7464.3164.31692.91765.090.57161.653.7283,190,820.005.319.297.1812.6280.4677.909.2814.251.31--0.179940.02-3.94-1.86-38.29-9.04-8.105.59
Merck KGaA2.45tn344.93bn3.70tn59.31k36.064.806.271.516.186.1843.8547.400.43812.005.07328,284.206.204.418.015.8462.3163.6914.1510.980.669415.820.34659.718.566.4253.7912.3717.665.92
Data as of Nov 29 2021. Currency figures normalised to Shionogi & Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

24.29%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 15 Jul 202021.44m6.88%
Daiwa Asset Management Co. Ltd.as of 29 Oct 20219.16m2.94%
Nikko Asset Management Co., Ltd.as of 05 Nov 20219.02m2.89%
The Vanguard Group, Inc.as of 05 Nov 20217.02m2.26%
Capital Research & Management Co. (World Investors)as of 30 Sep 20215.38m1.73%
Capital International KKas of 30 Oct 20205.21m1.67%
BlackRock Fund Advisorsas of 04 Nov 20215.10m1.64%
Harding Loevner LPas of 30 Sep 20214.92m1.58%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 04 Nov 20214.59m1.47%
Norges Bank Investment Managementas of 31 Dec 20203.85m1.24%
More ▼
Data from 31 Dec 2020 - 30 Sep 2021Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.